



ASO VISUAL ABSTRACT

ASO Visual Abstract: Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node-Negative T1 Triple-Negative Breast Cancer

Kai Huang, MD¹, James Jakub, MD², Emmanuel Gabriel, MD², Alvaro Moreno-Aspitia, MD³, and Sarah McLaughlin, MD²

¹Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA; ²Department of Surgery, Mayo Clinic Florida, Jacksonville, FL; ³Jacoby Center for Breast Health, Division of Hematology Oncology, Mayo Clinic Florida, Jacksonville, FL

For patients with clinical T1 node-negative triple-negative breast cancer (TNBC), overall survival of upfront surgery followed by adjuvant chemotherapy was not inferior to those who underwent neoadjuvant chemotherapy (NACT).

Neoadjuvant chemotherapy was associated with a better outcome in cT1c patients who attained pCR (<https://doi.org/10.1245/s10434-023-13977-4>).

